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Key Points for Decision Makers 
• The clinical and cost effectiveness evidence presented was based on a well-designed 
randomized controlled trial (RCT). The clinical data for the effectiveness of pertuzumab + 
trastuzumab + docetaxel appeared to be promising for the treatment of women with 
human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer 
(MBC). However, the overall survival data were immature. This poses problems for the 
assessment of longer-term clinical and cost effectiveness  
• The majority of patients treated in the RCT were trastuzumab naïve as, at the time patients 
were recruited, this was the norm. However, today in clinical practice, the majority of 
patients with HER2+ MBC receive trastuzumab for the treatment of early breast cancer. 
This may pose problems in the assessment of the relevance of the trial data to current 
clinical practice 
• The cost effectiveness evidence based on economic modelling of the RCT data suggests that 
it would be impossible to set a price at which pertuzumab + trastuzumab + docetaxel could 
ever meet acceptability criteria for cost effectiveness typically applied by the National 
Institute for Health and Care Excellence (NICE). This is an issue that needs further 
exploration. As a result, the NICE Decision Support Unit are undertaking a discussion paper 
for assessing technologies that are not cost effective at a zero price. 
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Abstract 
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of 
pertuzumab [Roche] to submit evidence for the clinical and cost effectiveness of pertuzumab + 
trastuzumab + docetaxel for the treatment of human epidermal growth factor receptor 2-
positive (HER2+) metastatic or locally recurrent unresectable breast cancer in accordance with 
the Institute’s Single Technology Appraisal (STA) process. The Liverpool Reviews and 
Implementation Group (LRiG) at the University of Liverpool was commissioned to act as the 
Evidence Review Group (ERG). This article summarizes the ERG’s review of the evidence 
submitted by the manufacturer and provides a summary of the Appraisal Committee’s (AC) 
initial decision. At the time of writing, final guidance had not been published by NICE. 
 
The clinical evidence was mainly derived from an ongoing phase III randomized double-blind 
placebo-controlled international multicentre clinical trial (CLEOPATRA), designed to evaluate 
efficacy and safety in 808 patients, which compared pertuzumab + trastuzumab + docetaxel 
(pertuzumab arm) with placebo + trastuzumab + docetaxel (control arm). Both progression-free 
survival (PFS) and overall survival (OS) were analysed at two data cut-off points – May 2011 
(median follow-up of 18 months) and May 2012 (median follow-up of 30 months). At both time 
points PFS was significantly longer in the pertuzumab arm (18.5 months compared with 12.4 
months in the control arm at the first data cut-off point and 18.7 months vs 12.4 months at the 
second data cut-off point). Assessment of OS benefit suggested an improvement for patients in 
the pertuzumab arm with a strong trend towards an OS benefit at the second data cut-off 
point; however, due to the immaturity of the OS data, the magnitude of the OS benefit was 
uncertain. Importantly, cardiotoxicity was not increased in patients treated with a combination 
of pertuzumab + trastuzumab + docetaxel. The ERG’s main concern with the clinical 
effectiveness data was the lack of mature OS data. An additional concern of the AC was that the 
majority of patients in the RCT were trastuzumab naïve, which does not reflect current clinical 
practice. 
 
The incremental cost effectiveness ratios (ICERs) generated by the manufacturer’s model is 
considered to be commercial in confidence data and therefore cannot be published. 
Nevertheless, the results of the manufacturer’s probabilistic sensitivity analyses suggest that 
pertuzumab + trastuzumab + docetaxel has a 0% probability of being cost effective at a 
willingness-to-pay of £30,000 per quality adjusted life year (QALY) gained when compared with 
trastuzumab + docetaxel. The ERG believes that more realistic estimates of the ICERs are 
considerably higher, almost double, those presented by the manufacturer. This is because the 
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ERG believes that due to the manner in which the economic model is constructed, the 
additional survival benefit following disease progression that is generated for patients treated 
with pemetrexed + trastuzumab + docetaxel are unrealistic. At the time of writing NICE had not 
made final decision regarding this technology but had instead referred the issue of the 
assessment of technologies that are not effective at a zero price to their Decision Support Unit 
for advice. 
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1 Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organization 
responsible for providing national guidance to the NHS in England and Wales on a range of 
clinical and public health issues, as well as the appraisal of new health technologies. The NICE 
Single Technology Appraisal (STA) process is specifically designed for the appraisal of a single 
health technology for a single indication, where most of the relevant evidence lies with one 
manufacturer or sponsor.(1) Typically, the process is used for new pharmaceutical products 
close to launch. The evidence for a STA is principally derived from a submission by the 
manufacturer/sponsor of the technology, which should be based on a specification developed 
by NICE. The manufacturer’s submission is critiqued by members of the independent Evidence 
Review Group (ERG) who produce a report to be considered by a NICE Appraisal Committee 
(AC). 
 
The AC considers the submissions from the manufacturer and the ERG alongside testimony 
from experts, patients and other stakeholders to formulate preliminary guidance. All 
stakeholders have an opportunity to comment on this preliminary guidance, after which the AC 
meets again to produce the final guidance (final appraisal determination [FAD]). This article 
presents a summary of the ERG report for the STA of pertuzumab + trastuzumab + docetaxel for 
the treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic or 
locally recurrent unresectable breast cancer. 
 
Full details of all relevant appraisal documents (including the appraisal scope, ERG report, 
manufacturer and consultee submissions, Appraisal Consultation Document [ACD], FAD and 
comments on each of these) can be found on the NICE website.(2) 
 
2 The Decision Problem 
Breast cancer is the most common malignancy in women in the UK. Approximately 50,000 
people were diagnosed with breast cancer in the UK in 2010, of whom 99% were women.(3) 
Approximately 25% of patients with breast cancer develop metastatic breast cancer (MBC).(4)  
 
Typically, patients who present with locally advanced or metastatic disease have been 
previously treated in the adjuvant setting for early breast cancer; between 5% and 10% of 
women initially present with de novo metastatic disease.(5-7) Patients with de novo disease are 
reported to have a better prognosis than those who have been previously treated for breast 
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cancer. A population study of de novo vs relapsed disease conducted in Texas, USA, reported a 
median overall survival (OS) of 39.2 months vs 27.2 months (p < 0.0001).(7) UK survival rates are 
reported to be lower than rates in much of the rest of Europe and North America, but do 
appear to be improving.(8, 9) Based on 34,598 cases from six UK-based cancer registries, a recent 
study estimated that the 5-year survival rate for patients with MBC is 79% and the 10-year 
survival rate is 71%.(10)  
 
It has been estimated that 23% of patients who present with MBC have tumours that 
overexpress HER2.(4) HER2+ MBC is considered to be an aggressive form of disease and is 
associated with higher rates of recurrence, shorter progression-free survival (PFS) and shorter 
OS than for patients with tumours that do not overexpress HER2.(11-17) 
 
There is minimal variation or uncertainty about best practice in the treatment of patients with 
HER2+ MBC. In the UK, based on NICE guidance,(18, 19) trastuzumab + taxane-based 
chemotherapy (docetaxel or paclitaxel) is the standard first-line treatment for patients with 
HER2+ MBC. Despite recent advances in the treatment of HER2+ MBC, including the proven 
efficacy of trastuzumab + docetaxel,(20) it is argued that a significant need still exists for new 
treatments with improved response rates.(4) 
 
Pertuzumab (Roche) is a monoclonal antibody that binds to HER2 receptors on the surface of 
tumours and prevents HER2 dimerizing with other members of the HER family (HER1, HER3 and 
HER4).(4) This results in inhibition of the signalling inside the cell that leads to tumour growth 
and hence pertuzumab is considered to be the first in a new class of targeted cancer treatments 
called ‘HER2 dimerization inhibitors’.(4) Pertuzumab is considered to be particularly effective in 
combination with trastuzumab, another type of monoclonal antibody directed against HER2, as 
the combination leads to an improved block of the signalling pathway.(4) Pertuzumab has 
recently been approved by the European Medicines Agency (EMA) for use “in combination with 
trastuzumab and docetaxel in adults with HER2-positive metastatic or locally recurrent 
unresectable breast cancer, who have not received previous anti-HER2 therapy or 
chemotherapy for their metastatic disease”.(21)  
 
NICE developed a scope for the assessment of pertuzumab which specified that the clinical and 
cost effectiveness of this drug should be established within its licensed indication. The 
population and intervention specified in the NICE scope and addressed by the manufacturer 
were the same as those approved by the EMA.(21) Trastuzumab in combination with a taxane 
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(docetaxel or paclitaxel) was the comparator specified in the NICE scope and addressed by the 
manufacturer. Outcomes specified in the NICE scope and addressed by the manufacturer 
included (but were not limited to) OS, PFS, response rates, adverse events (AEs) and health-
related quality of life. As specified in the final NICE scope, the cost effectiveness of treatments 
were expressed by the manufacturer in terms of the incremental cost per quality-adjusted life 
year (QALY) gained. The time horizon was lifetime (maximum 25 years), which is sufficiently 
long to reflect differences in costs or outcomes between the technologies. Costs were 
considered from an NHS and Personal Social Services perspective. No specific subgroups were 
identified in the decision problem. In addition, no potential equity or equality issues were 
identified.  
 
3 Independent Evidence Review Group Report 
The evidence provided by the manufacturer comprises an initial submission and the 
manufacturer’s response to the ERG’s request for clarification on a number of issues.(4) The ERG 
report(22) is a critical review of the evidence for the clinical and cost effectiveness of the 
technology. It has the following three aims: 
 
• To assess whether the manufacturer’s submitted evidence conforms to the methodological 
guidelines issued by NICE 
• To assess whether the manufacturer’s interpretation and analysis of the evidence are 
appropriate 
• To indicate the presence of other sources of evidence or alternative interpretations of the 
evidence that could help inform the development of NICE guidance  
 
In addition to providing this detailed critique, the ERG modified a number of key assumptions 
and parameters within the manufacturer’s economic model to examine the impact of such 
changes on cost effectiveness results.  
 
The majority of the clinical effectiveness evidence was derived from a single randomized 
controlled trial (RCT) known as CLEOPATRA, which at the time of the manufacturer’s literature 
search had been described in one full peer-reviewed publication.(23) Additional sources of data 
used by the ERG included a subsequently published paper on the CLEOPATRA trial,(24) the 
Clinical Study Report (CSR)(25) and the updated CSR.(26)] The latter two documents were both 
provided by the manufacturer at the ERG’s request.  
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3.1 Clinical Evidence 
CLEOPATRA(24) is an ongoing phase III randomized double-blind placebo-controlled international 
multicentre clinical trial involving 808 patients with previously untreated HER2+ MBC. The trial 
was designed to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel 
(pertuzumab arm) compared with placebo + trastuzumab + docetaxel (control arm). Both OS 
and PFS were analysed at two data cut-off points – May 2011 (median follow-up of 18 months) 
and May 2012 (median follow-up of 30 months). The primary outcome was PFS assessed by an 
independent review facility (IRF) at the first data cut-off point. To date, OS analyses are only 
interim as the data are still not mature. Final OS data are planned to be presented after 
approximately 385 deaths (expected mid to late 2014). Interim rates of OS are summarized 
alongside the rates for PFS in Table 1. A significant improvement in both IRF- and local 
investigator-assessed PFS of 6.1 months was reported at the first data cut-off point and a 
similar finding (6.3 months) was reported for local investigator-assessed PFS at the second data 
cut-off point. A significant improvement in OS was only reported at the second data cut-off 
point; whilst P<0.05 at the first time point, the estimated hazard ratio did not meet the O’Brien-
Fleming stopping boundary of the Lan-DeMets α-spending function so the finding was not 
considered to be significant. 
 
Results from planned subgroup analyses were generally consistent with the results from the 
overall study population. However, it appeared that OS was higher in patients in the control 
arm in the subgroup with non-visceral disease, although the subgroup was small (n = 178) and 
there were few events. The difference therefore was not statistically significant and the 
confidence intervals (CI) around the hazard ratio (HR) were wide (HR 1.42, 95% CI: 0.71 to 2.84). 
In addition to the planned subgroup analyses, and at the behest of the EMA,(27) an exploratory 
subgroup analysis of patients who had previously received trastuzumab was also conducted at 
the first data cut-off point (May 2011). This analysis was requested because, in current clinical 
practice, the majority of patients are likely to have received prior trastuzumab for the 
treatment of early breast cancer. Again, patient numbers were small (n = 88), but, findings were 
consistent with those for the overall population (subgroup findings: PFS, HR 0.62, 95% CI: 0.35 
to 1.07; OS, HR 0.68, 95% CI: 0.30 to 1.55).  
 
A summary of key AEs reported from the second data cut-off point is presented in Table 2. The 
main difference between the two treatment arms were a higher incidence of serious adverse 
events (SAEs) and AEs leading to dose interruption or modification in the pertuzumab arm than 
in the control arm. Since trastuzumab is thought to increase the risk of cardiotoxicity, particular 
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emphasis was placed on collecting data on cardiac disorders. Relatively few cardiac events were 
reported in either arm (Table 2). The most common AEs in both arms (pertuzumab vs control) 
were alopecia (60.8% vs 60.6%), diarrhoea (68.1% vs 48.2%), neutropenia (52.9% vs 49.7%), 
nausea (43.9% vs 42.4%) and fatigue (38.0% vs 37.4%). Some AEs appeared to be exacerbated 
by treatment with docetaxel (in particular diarrhoea, neutropenia, and mucositis) and once this 
drug was stopped, there was little difference in terms of the incidence of AEs between patients 
treated with pertuzumab + trastuzumab and those treated with trastuzumab alone. 
 
Because the evidence from CLEOPATRA(24) included docetaxel as the taxane regimen,   
additional evidence for the relative effectiveness of paclitaxel + trastuzumab was derived from 
a descriptive indirect comparison of two studies(20, 28) conducted in the metastatic setting. These 
compared docetaxel or paclitaxel + trastuzumab with taxane monotherapy; in both trials, 
taxanes were administered every 3 weeks. The results implied that regimens containing 
trastuzumab and a taxane are superior to those of a taxane alone (Table 3) and that 
trastuzumab + docetaxel may be the most efficacious. Evidence was also presented from a large 
RCT of 4950 patients in the adjuvant setting comparing four different taxane regimens, albeit all 
delivered as monotherapies: once weekly or 3-weekly docetaxel or paclitaxel.(29) The factorial 
design of the trial enabled 3-weekly paclitaxel to be compared to three experimental regimens: 
once-weekly paclitaxel, 3-weekly docetaxel and once-weekly docetaxel regimens. Compared to 
3-weekly paclitaxel, the authors of the RCT(29) reported significant improvements in disease-free 
survival (DFS) (HR 1.27, 95% HR: 1.03 to 1.57) and OS (HR 1.32; 95% HR: 1.02 to 1.72) for once-
weekly paclitaxel. Significant differences were also observed in DFS for 3-weekly docetaxel (HR 
1.23, 95% HR: 1.00 to 1.52) but not OS (HR 1.13, 95% HR: 0.88 to 1.46). Once-weekly docetaxel 
yielded neither significant gains in DFS (HR 1.09, 95% HR: 0.89 to 1.34) or OS (HR 1.02, 95% HR: 
0.80 to 1.32). In their submission,(4) the manufacturer notes that weekly paclitaxel and 3-weekly 
docetaxel regimens were associated with comparable 5-year DFS (81.5% and 81.2% 
respectively) and OS (89.7% and 87.3% respectively).  
 
3.1.1 Critique of Clinical Evidence and Interpretation 
The CLEOPATRA trial(23) is of good methodological quality with minimum risk of bias. The 
population in the study largely reflects people who would normally be eligible for trastuzumab- 
and docetaxel-based treatment outside of the clinical trial setting (i.e. with a 12-month disease-
free interval following previous treatment with chemotherapy, which is likely to have included 
docetaxel). However, only a minority of patients (10.9%) in the trial had previously been treated 
with trastuzumab for early breast cancer. In current clinical practice, a much greater proportion 
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of patients would be pre-treated with trastuzumab. This concern was also raised by the EMA.(27) 
The results of the exploratory subgroup analysis including the small number of patients who 
had previously received trastuzumab were noted, as were the conclusions of the EMA,(27) i.e. 
that these data, alongside those from the phase II BO17929 study(30) (which demonstrated 
activity of the pertuzumab + trastuzumab combination in 66 people previously treated with 
trastuzumab in the metastatic setting) support the efficacy of pertuzumab in people pre-
treated with trastuzumab.  
 
Another potentially important subgroup difference noted by the ERG (and also by the EMA (27)) 
involved patients with and without visceral disease. Patients with non-visceral disease 
appeared to gain the smallest benefit from the addition of pertuzumab. The ERG noted that the 
manufacturer suggested that the discrepancy may be attributable to the small number of 
patients with non-visceral disease in the trial and some differences between treatment arms in 
baseline characteristics. 
 
A final uncertainty identified by the ERG in relation to the efficacy evidence from CLEOPATRA(23) 
concerned the OS data. It was not possible to estimate the absolute difference in median OS 
between patients treated in the pertuzumab arm and those in the control arm because of 
immature data. This has important implications when trying to model OS for assessing cost 
effectiveness. 
 
Regarding the additional supporting evidence for different types of trastuzumab + taxane 
regimens, the ERG noted that the indirect evidence from the two trials(20, 28) could be described 
as a naïve indirect comparison. Such a comparison has been criticized in the literature for 
discarding the within-trial comparison, increasing the risk of bias and presenting estimates 
without a measure of uncertainty (e.g. 95% CIs).(31) The merit of using the trials in any type of 
comparison with each other may also be questioned, as apparent differences between the trials 
exist in terms of the patient populations. For example, of patients treated with a paclitaxel 
regimen, 98% had received prior adjuvant chemotherapy and 92% prior hormonal therapy,(28) 
compared with 69% and 45%, respectively, of patients who received trastuzumab + docetaxel 
or docetaxel alone.(20) Furthermore, it is noted by the ERG that in CLEOPATRA,(23) the 
proportions of patients pre-treated with chemotherapy (47%) or hormonal therapy (25%) were 
even lower. A number of issues were also highlighted by the ERG regarding the data from the 
head-to-head comparisons of taxane regimens.(29) First, and most obviously, the taxane 
regimens under investigation were monotherapies and not offered in combination with 
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trastuzumab (or pertuzumab). Second, the setting for the interventions was the adjuvant 
setting and so none of the patients had metastatic disease. Third, fewer than 20% of the 
patients enrolled into the trial had HER2+ disease. Finally it is noted that all patients had 
received prior chemotherapy.  
 
The ERG noted that no safety data were presented by the manufacturer from the three trials 
offering supportive evidence.(20, 28, 29) While safety data were presented in the published paper 
of the trial in the adjuvant setting,(29) the applicability of these data to the current decision 
problem could be questioned given this was a population of patients treated with a taxane 
monotherapy in the adjuvant setting of whom only a minority had HER2+ disease. 
 
 
3.1.2 Evidence Review Group Conclusions on the Submitted Clinical Evidence 
CLEOPATRA(23) is a relatively large trial of good methodological quality. Local investigator and 
central IRF-assessed reviews of PFS both suggest that patients in the pertuzumab arm 
experience an increase in PFS of approximately six months. A significant improvement in OS 
was reported at a median of 30 months follow-up (second data cut-off point, May 2012) 
although the data are not fully mature and so the difference in median OS cannot be estimated. 
No new safety concerns were identified. Importantly, cardiotoxicity was not increased in 
patients treated with a combination of pertuzumab + trastuzumab.  
 
3.2 Cost effectiveness Evidence 
The manufacturer’s submission(4) included a literature review of cost effectiveness evidence. It 
was reported that there were no relevant published economic evaluations available for 
consideration.  
 
The manufacturer developed a de novo economic model using a partitioned survival approach 
structured with three patient health states (PFS [stable disease], progressed disease and death). 
The patient population included in the model was based on the participants enrolled in the 
CLEOPATRA trial(23) and the model was populated with data from the second data cut-off point 
in that trial.(24) Second-line treatments applied in the model were capecitabine and vinorelbine. 
In the base case, exponential survival models were appended to Kaplan–Meier data to allow 
PFS and OS to be forecast for a period of 25 years, and the perspective was that of the UK NHS. 
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The external validity of the model was compared with the survival of patients included in a 
registry of 523 people diagnosed with HER2+ MBC between 2002 and 2009 in Munich, 
Germany.(32) It was reported that the model results showed strong face validity when compared 
with these data. 
 
Drug costs were reported to be taken from the British National Formulary 2012,(33) 
administration costs from NHS Reference costs for 2011/12(34) and pharmacy costs from Millar 
et al.(35) and PSSRU 2012.(36) Monthly supportive care costs during PFS and post progression 
were as described in the NICE clinical guideline for advanced breast cancer,(19) excluding the 
one-off costs for a social worker visit, a consultant outpatient appointment and a computed 
tomography scan in the PFS state. Costs for cardiac monitoring were also included during the 
PFS state. End-of-life costs were estimated by inflating the figures calculated by Guest et al. 
2006(37) to current prices using inflation indices for Hospital and Community Health Services 
(PSSRU).(36) AE costs were only included for AEs reported to occur in 2% or more people in 
either arm of the CLEOPATRA trial(23) at grade 3, 4 or 5 severity. It was assumed that treatment 
regimens of trastuzumab + docetaxel and trastuzumab + paclitaxel had the same toxicity 
profile.  
 
The manufacturer conducted a literature search to identify all potentially relevant utility scores 
that had been used in health technology evaluations for MBC. This search was an update of a 
previous search that had been carried out for the NICE Technology Appraisal of bevacizumab in 
combination with capecitabine (TA263).(38) No new relevant studies were identified and so the 
manufacturer concluded that the most appropriate approach was to use the model outlined by 
Lloyd et al.(39) to estimate QALYs. This approach was used in TA263(38) and has also been used in 
a number of other NICE Technology Appraisals for MBC.  
 
Both costs and benefits were discounted at 3.5%. However, AE costs were only applied in week 
1 in the model and are therefore not discounted.  
 
It is reported by the manufacturer that the model was validated at two advisory board 
meetings and by a health economics consultancy. Model functionality was checked during this 
process and the clinical inputs and assumptions were validated. Extrapolation of data was 
discussed with an academic health economist and two panels of clinicians. These advisors 
noted that although subject to uncertainty, the extrapolation approach employed by the 
manufacturer appeared reasonable given the evidence currently available. 
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Deterministic and probabilistic sensitivity analyses were undertaken. Parameters varied in the 
deterministic analyses included treatment costs, utilities, parametric functions used to 
extrapolate trial data, discounting rates (for costs and utilities) and the time horizon.  
Probabilistic sensitivity analyses were undertaken by varying costs for best supportive care and 
second-line treatment (both using lognormal distributions) and utilities (using beta 
distributions). 
 
The base-case ICERs generated by the manufacturer’s model were all marked as commercial in 
confidence data as were the ICERs generated from the deterministic and probabilistic sensitivity 
analyses.  The deterministic sensitivity analyses showed the model to be most sensitive to the 
long term extrapolation of PFS and OS, whilst the probabilistic sensitivity analyses suggested 
that pertuzumab + trastuzumab + docetaxel had a 0% probability of being cost effective at a 
willingness-to-pay of £30,000 per QALY gained when compared with trastuzumab + docetaxel.  
 
3.2.1 Critique of Cost effectiveness Evidence and Interpretation 
The ERG considered that the manufacturer’s economic model was logically structured and 
competently implemented with adequate annotation to allow most features to be readily 
understood. In the ERG report,(22) the ERG commented on major and minor issues of concern. 
The latter related to costs and utilities and only had a minor impact on the size of the final ICER. 
Hence, only major issues of concern are considered here. 
 
As part of its clarification request to the manufacturer, the ERG requested Kaplan–Meier 
survival estimates at each event time, for each treatment arm in the CLEOPATRA trial(23) for OS, 
PFS, time to off treatment (TTOT) and post-progression survival (PPS) censored at the date of 
data cut-off. These data were requested for the overall trial population as well as for patients 
with and without visceral disease. The manufacturer responded that by requesting these data, 
the ERG was exceeding their remit and so these data were not provided. However, the 
manufacturer did provide information from its communications with the EMA. This included 
some data describing subgroups and time-to-event information, albeit not censored at the date 
of data cut-off; therefore the available data appeared to suffer from systematic bias because of 
inappropriate censoring at the last trial observation date.  
 
The ERG countered that these matters did fall within its remit because, as part of the STA 
process, the ERG is required to comment on the robustness and accuracy of the submitted 
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models, the data used to populate the models and, where possible, to carry out sensitivity 
analyses. As alternative assumptions in time-to-event analyses may be critical drivers of any 
model, and, as subgroup differences were deemed sufficient to require careful consideration in 
terms of efficacy and safety by the EMA,(27) the data requested by the ERG were clearly relevant 
to the appraisal. Without these data, the ERG was unable to consider the effect of alternative 
projections for PFS, OS, TTOT and PPS. Additional information detailing communications 
between the manufacturer and the regulator did enable the ERG to address the matters in 
broad terms, but did not enable the ERG to provide the AC with the results of fully detailed 
economic sensitivity analyses. Although the ERG considered that the Kaplan–Meier data 
provided were probably subject to serious bias, the ERG did conduct an exploratory projective 
modelling exercise to assess the sensitivity of the manufacturer’s method of curve-fitting to 
alternative assumptions. 
 
The ERG agreed with the manufacturer that adding pertuzumab to trastuzumab + docetaxel 
results in an increase in PFS but considered that there was uncertainty about the size of this 
survival gain. In the model, an exponential projection was applied to each trial arm by the 
manufacturer in its base case. The ERG considered that long-term hazard trends should only be 
estimated based on the segment of the trial data after 600 days. Moreover, the ERG observed 
that, if the final data points showing evidence of serious bias (sudden upward rise) were 
ignored, then the long-term hazard trends appeared to follow simple near-linear trajectories. 
On this basis, the ERG fitted linear trend lines to estimate long-term hazard trends for each trial 
arm and applied these to project PFS from day 600 onwards. As a result, the mean difference in 
PFS between the two treatment arms estimated by the ERG was substantially smaller than the 
difference estimated by the manufacturer. 
 
The ERG did not agree with the manufacturer that there was a large difference in OS between 
treatments. In the manufacturer’s base case, the majority of the estimated life extension 
occurred in the post-progression health state where a higher risk of death in the control arm 
compared with the pertuzumab arm was assumed. The ERG considered this to be inappropriate 
and assumed that there was no evidence of any difference in survival between treatment arms 
after progression. Thus, by applying the mortality trend from the Munich Register(32) to both 
arms in the model, the PPS gain estimated by the manufacturer was substantially reduced. The 
ERG also re-estimated OS using the PFS estimates, adjusting them for any difference in the 
proportion of patients dying before disease progression. Specifically, it used the estimated PFS 
gain and added to it the additional benefit after progression due to the small difference 
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between the two treatment arms in the proportion of patients still alive after disease 
progression, and assumed that the long-term post-progression hazard was the same in both 
arms. This approach reduced the OS gain to a similar magnitude to that calculated using the 
Munich register data.(32) Both approaches gave similar ICERs, which were substantially higher 
than the ICERs estimated in the manufacturer’s base case. 
 
3.2.2 Evidence Review Group Conclusions on the Submitted Cost effectiveness Evidence 
The ERG considers that the OS data are not mature and that modelling using the currently 
available data is therefore limited. The ERG agrees with the manufacturer that pertuzumab + 
trastuzumab + docetaxel compared with trastuzumab + docetaxel has a 0% probability of being 
cost effective at a willingness-to-pay of £30,000 per QALY gained. However, the ERG believes 
the true estimate of the ICER to be considerably higher than that presented by the 
manufacturer. This large discrepancy is attributable to the ERG’s belief that analysis of the 
available trial data shows no additional benefit in survival following disease progression, unlike 
the estimates given in the manufacturer’s base case.  
 
4 National Institute for Health and Care Excellence Guidance 
At the first AC meeting the committee did not recommend pertuzumab + trastuzumab + 
docetaxel within its marketing authorization (i.e. for the treatment of people with HER2+ 
metastatic or locally recurrent unresectable breast cancer who have not received previous anti-
HER2 therapy or chemotherapy for their metastatic disease). This decision was contested, and a 
second AC meeting was held. At the time of writing (May 2014), a final decision from NICE had 
not been published.  
 
 
4.1 First Appraisal Committee Meeting 
The AC agreed that, compared with trastuzumab + docetaxel, the addition of pertuzumab 
offered a benefit in PFS and OS but because of the immaturity of the OS data, the magnitude of 
the OS benefit was uncertain. It was concluded that there was insufficient evidence on which to 
base specific recommendations for people with visceral and non-visceral disease because of the 
small number of patients and events in the subgroup with non-visceral disease. The AC noted 
that the incidence of SAEs in the CLEOPATRA trial(23) was higher in the pertuzumab arm than in 
the control arm, as were the incidences of AEs leading to dose interruption or modification. 
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The AC noted the limitations of the naïve indirect comparison of docetaxel and paclitaxel 
highlighted by the ERG, and agreed that these results should be treated with caution. The 
clinical specialist told the AC that in clinical practice, 3-weekly docetaxel and weekly paclitaxel 
regimens are regarded as clinically similar and that the similar clinical effectiveness of these 
two regimens had been accepted by the AC in a previous technology appraisal (bevacizumab in 
combination with a taxane for the first-line treatment of metastatic breast cancer).[38] The AC 
concluded that it was reasonable to assume similar clinical effectiveness between 3-weekly 
docetaxel and weekly paclitaxel when used in combination with pertuzumab and trastuzumab. 
However, the AC heard from the clinical specialist that people who had experienced a 12-
month disease-free interval following previous treatment with chemotherapy (as in 
CLEOPATRA(23)) might be expected to have a better prognosis than the whole population with 
HER2+ MBC. The clinical specialist also highlighted that only a minority (10.9%) of the 
randomized population in CLEOPATRA(23) had received previous treatment with trastuzumab in 
the adjuvant setting. This trial population therefore was not representative of a UK population 
as, in the UK, trastuzumab in the adjuvant or neoadjuvant setting is standard treatment. Hence, 
the AC questioned whether the trial population of CLEOPATRA(23) was representative of the 
population who would receive pertuzumab in clinical practice. It also noted comments from the 
clinical specialist that although pertuzumab is licensed for use in combination with trastuzumab 
and docetaxel, it may be more likely to be used in combination with trastuzumab and paclitaxel 
in clinical practice because a large majority of people would have had prior treatment with 
docetaxel in the adjuvant setting and hence a different taxane might be preferred. 
 
Noting the difference in PPS estimates reported by the manufacturer and the ERG, the AC 
discussed the relationship between PFS and OS gain in the CLEOPATRA trial.(23) The AC heard 
from the clinical specialist that the statistically significant benefit of pertuzumab + trastuzumab 
+ docetaxel in terms of PFS could be expected to be translated into a similar, if not greater, gain 
in OS. However, the AC considered that if OS gain exceeded the PFS gain, this implied a 
continuing beneficial drug effect in the disease progression phase, after the drug had been 
stopped. The biological plausibility of pertuzumab having a carry-over effect after treatment 
has been stopped was therefore discussed. The clinical specialist explained that this carry-over 
effect had been seen when tamoxifen was used in the adjuvant setting but would not 
necessarily be seen with HER2-targeted treatments in MBC. The AC heard from the 
manufacturer that there had been other clinical trials of MBC with trastuzumab that had shown 
an OS gain exceeding the PFS gain. It was noted that for MBC, these trials compared treatment 
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with trastuzumab plus a taxane against a taxane alone(20, 28) or trastuzumab and an aromatase 
inhibitor against an aromatase inhibitor alone.(40) The AC considered that it did not necessarily 
imply that the same effect would be seen with the addition of pertuzumab to trastuzumab and 
docetaxel compared with trastuzumab and a taxane alone. The AC concluded that there may, 
therefore, be various hypothetical explanations for the presence of a carry-over effect with 
pertuzumab after stopping the drug at disease progression. It considered that although some 
post-progression benefit might present as a carry-over effect, the manufacturer’s calculation 
that the gain was more than twice as great in the post-progression phase after pertuzumab had 
been stopped compared to when the patients were receiving the drug in the pre-progression 
state was likely to be over-optimistic. Given that the immature OS data from the trial did not 
allow a robust assessment of any PPS benefit, there remained considerable uncertainty around 
the presence, or magnitude, of any post-progression benefit from the addition of pertuzumab 
to trastuzumab + docetaxel. 
 
Finally, the AC considered the ICERs per QALY gained for pertuzumab + trastuzumab + 
docetaxel compared with trastuzumab + docetaxel presented by the manufacturer and by the 
ERG in its exploratory analyses. It noted that the cost effectiveness estimates from both the 
manufacturer and the ERG were outside the range normally considered to represent a cost-
effective use of NHS resources. It concluded that pertuzumab + trastuzumab + docetaxel would 
not be a cost-effective use of NHS resources for treating HER2+ MBC compared with 
trastuzumab + docetaxel alone. 
 
4.2 Second Appraisal Committee Meeting and Final Appraisal Determination 
At the time of writing, the decisions reached from the second meeting had not been made 
public and a final decision from NICE was still outstanding. The NICE website(2) notes “the 
manufacturer’s comment that it is not possible to set a price at which pertuzumab would meet 
current acceptability criteria for cost effectiveness” and states that the NICE Decision Support 
Unit (DSU) were undertaking a discussion paper for “assessing technologies that are not cost 
effective at a zero price.” The next steps for reaching a final decision will then be taken by NICE 
following the outcome of the DSU’s explanations. 
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5 Conclusion 
A clinical benefit of pertuzumab + trastuzumab + docetaxel over trastuzumab + docetaxel in 
terms of PFS is evident from the CLEOPATRA trial.(23) However, because the trial data are 
immature, uncertainties exist as to whether OS is also improved. Because of the small number 
of study patients who were pre-treated with trastuzumab in the adjuvant or neo-adjuvant 
setting, the AC also considered there to be grounds for uncertainty as to the generalizability of 
the trial results to clinical practice. 
 
Pertuzumab + trastuzumab + docetaxel do not appear to be cost effective compared to 
trastuzumab + docetaxel when using typically accepted criteria. This is true whether accepting 
the results from the manufacturer’s model in which there is evidence of additional benefit in 
terms of survival following disease progression, or accepting he ERG’s approach that assumed 
there would be no additional benefit in terms of survival following disease progression. 
Unfortunately, the AC was limited in its consideration of the evidence by a lack of the requested 
additional analyses requested from the manufacturer by the ERG.  The lack of these analyses 
prevented the ERG from carrying out robust sensitivity analyses of alternative survival 
assumptions. 
   
Of particular note is the observation by the manufacturer that there is no price at which 
pertuzumab used in combination chemotherapy in this population could be deemed cost 
effective by NICE. Although this situation is uncommon, it cannot be considered an artefact of 
the NICE methods of appraisal, but is fully consistent with the principles of economic 
evaluation. Any intervention which generates sufficient additional patient survival linked to 
substantial additional treatment costs can lead to such a situation (e.g. in chronic 
relapsing/remitting conditions which require repeated high-cost in-patient rescue 
interventions, or where extended survival also involves additional expensive co-medication 
costs). In such circumstances, it is possible that an incremental cost per patient can be 
generated, excluding the additional cost of the appraised intervention, which is sufficient to 
result in an ICER greater than any specific maximum willingness-to-pay of the funder. A 
treatment may just be too expensive because it is linked to other additional costs which cannot 
be offset by cost savings. 
 
Finally, reviewers of this paper commented that the transparency of the NICE appraisal process 
may appear to be undermined when data, in particular estimates of ICERs, are withheld 
because they are deemed to be commercially or academically in confidence. The ERG is 
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cognizant of the difficulties that this presents and endeavours whenever possible to present as 
full a picture of the data as possible. 
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Table 1 Main efficacy findings from CLEOPATRA trial 
 
Outcome Pertuzumaba Controlb  Result between arms 
PFS (IRF assessment, May 2011), n 
Median time to event (months) 
402 
18.5 
406 
12.4 
HR 0.62 (95% CI: 0.51 to 0.75) 
p < 0.0001 
PFS (local assessment, May 2011), n  
Median time to event (months) 
402 
18.5 
406 
12.4 
HR 0.65 (95% CI: 0.54 to 0.78) 
PFS (local assessment, May 2012), n 
Median time to event (months) 
402 
18.7 
406 
12.4 
HR 0.69 (95% CI: 0.58 to 0.81) 
p < 0.0001 
OS (May 2011), n 
Median time to event (months) 
402 
not reached 
406 
not reached 
HR 0.64 (95% CI: 0.47 to 0.88) 
p = 0.0053 
OS (May 2012), n 
Median time to event (months) 
402 
not reached 
406 
37.6 
HR 0.66 (95% CI: 0.52 to 0.84) 
p = 0.0008 
Objective response (IRF assessment, 
May 2011),c n 
Responders 
ORR (%) 
95% CI for ORR (%)  
 
343 
275  
80.2 
(75.6 to 84.3) 
 
336 
233  
69.3 
(64.1 to 74.2) 
 
 
 
10.8  
(4.2 to 17.5), p = 0.001 
Objective response (local 
assessment, May 2011),c n 
Responders 
ORR (%)  
95% CI for ORR (%) 
 
367 
284 
77.4 
Not reported 
 
371 
253  
68.2 
Not reported 
 
 
 
p = 0.0049, stratified analysis 
This table is adapted from data presented in the manufacturer’s submission(4) and tabulated in Fleeman et al(22) (Crown 
copyright) 
CI confidence interval; HR hazard ratio; IRF independent review facility; ORR objective response rate; OS overall 
survival; PFS progression-free survival 
a Pertuzumab = pertuzumab + trastuzumab + docetaxel 
b Control = placebo + trastuzumab + docetaxel 
c Objective response was only analysed at the first data cut-off point (May 2011) 
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Table 2 Summary of adverse events reported in the CLEOPATRA trial (second data cut-off point, 
May 2012)a 
 
Adverse events Pertuzumabb (%) 
(n = 408) 
Controlc (%) 
(n = 396) 
Any AE/ any grade 100.0 98.7 
Any AE/ grade 3+ 76.2 73.5 
Treatment-related AEs 97.3 96.2 
SAE 36.3 29.0 
All cardiac disorders 15.4 17.4 
Cardiac SAE 1.7 3.5 
AE leading to discontinuation of any study medication 30.6 29.2 
AE leading to dose interruption or modification 61.8  54.3 
AE leading to death 2.0 3.0 
The table is adapted from data presented in the manufacturer’s submission(4) and Fleeman et al.(22) (Crown copyright) 
AE adverse event; SAE serious adverse event 
a No tests for statistical significance between groups were conducted 
b Pertuzumab=pertuzumab + trastuzumab + docetaxel  
c Control=placebo + trastuzumab + docetaxel 
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Table 3 Comparison of efficacy findings for trastuzumab + taxane vs taxane alone in metastatic 
breast cancer 
 
Key endpoints Trastuzumab + docetaxel vs 
docetaxel(20) 
Trastuzumab + paclitaxel vs 
paclitaxel(28) 
Trastuzumab 
+ docetaxel 
(n = 92) 
Docetaxel 
(n = 94) 
Trastuzumab 
+ paclitaxel 
(n = 92) 
Paclitaxel 
(n = 96) 
Median OS (months) 31.2  22.7 22.1  18.4  
 P=0.0325 P=0.17 
Median TTP (months) 11.7  6.1  6.9  3.0  
 P=0.0001 P<0.001 
ORR (%) 61  34  38  16  
 P=0.0002 P<0.001 
This table is adapted from data presented in the manufacturer’s submission(4) and Fleeman et al.(22) (Crown copyright) 
ORR objective response rate; OS overall survival; TTP time to progression 
 
 
 
 
 
 
